Rubicon research Limited has notified stock exchanges about GST inspection proceedings initiated by authorities at its offices in Thane and Ambernath on January 30, 2026. The company filed the intimation under Regulation 30 of SEBI listing regulations to keep investors informed about the regulatory development.

Inspection Details and Timeline

The GST authorities commenced the inspection proceedings under Section 67 of the Maharashtra Goods and Services Tax Act, 2017. The inspection covered the company's offices located in Thane and Ambernath, with authorization presented to company officials at approximately 11:15 a.m. on January 30, 2026.

Company Response and Operations

Rubicon Research Limited stated it is extending full cooperation to the GST officials and providing all requisite information and clarifications. The company emphasized that its business operations continued as usual and were not impacted due to the inspection proceedings.

The management highlighted the company's commitment to maintaining high standards of compliance with all applicable laws and regulations, including prompt payment of applicable taxes. This stance reflects the company's approach to regulatory adherence across its operations.

Expected Impact Assessment

Based on initial assessment, the company does not reasonably expect the outcome of these proceedings to have any material impact on its financials or operations. This preliminary evaluation suggests the inspection is likely part of routine regulatory oversight rather than indicating specific compliance concerns.

Regulatory Compliance

The notification was filed under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders. The company secretary and compliance officer Deepashree Tanksale signed the intimation, maintaining proper corporate governance protocols during the regulatory process.

Rubicon Research Limited has announced that its board of directors will convene on February 3, 2026, to review and approve the company's quarterly financial performance. The meeting has been scheduled in accordance with regulatory requirements under SEBI guidelines.

Board Meeting Details

The pharmaceutical company informed stock exchanges on January 27, 2026, about the upcoming board meeting scheduled for Tuesday, February 3, 2026. The primary agenda includes consideration and approval of unaudited standalone and consolidated financial results for specific reporting periods.

Financial Results Coverage

The board will review comprehensive financial performance covering both quarterly and nine-month periods ended December 31, 2025. The results will encompass both standalone and consolidated financial statements, providing stakeholders with a complete view of the company's operational and financial performance during the specified periods.

Trading Window Restrictions

In compliance with the company's Code of Conduct for Prevention of Insider Trading, specific trading restrictions have been implemented. The trading window for dealing in company shares closed on January 1, 2026, and will remain suspended until 48 hours after the official announcement of the unaudited financial results.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results or other material matters are to be considered. The notification was signed by Company Secretary and Compliance Officer Deepashree Tanksale and submitted to both BSE Limited and National Stock Exchange of India Limited.

The company operates manufacturing facilities in Ambernath and Satara, Maharashtra, with its registered office and R&D center located in Thane. Rubicon Research Limited, formerly known as Rubicon Research Private Limited, continues to maintain its operational base in Maharashtra while serving the pharmaceutical sector.